Back
Menu
Cytomegalovirus (CMV), generally asymptomatic in immunocompetent children and adults, is a potentially significant disease in immunocompromised hosts, neonates and pregnant females.
Tests generally appear in the order most useful for common clinical situations
| Test name: Cytomegalovirus Rapid Culture |
| ARUP #: 0065004 |
| Methodology: Cell Culture/Immunofluorescence |
| Use: Rapid test to diagnose CMV infection Gold standard test for tissue High sensitivity and specificity |
| Test name: Cytomegalovirus by PCR |
| ARUP #: 0060040 |
| Methodology: Qualitative Polymerase Chain Reaction |
| Use: Rapid test to diagnose CMV in immunocompromised patients or solid organ donors (not tissue donors) May be performed on amniotic fluid |
| Limitations: PCR on amniotic fluid should be performed >21 weeks gestation to reduce risk of false negatives |
| Test name: Cytomegalovirus by PCR, Whole Blood or Bone Marrow |
| ARUP #: 0060031 |
| Methodology: Qualitative Polymerase Chain Reaction |
| Use: Rapid test to diagnose CMV infection |
| Test name: Cytomegalovirus, Quantitative PCR |
| ARUP #: 0051813 |
| Methodology: Quantitative Polymerase Chain Reaction |
| Use: Diagnose CMV infection Monitor disease state in solid organ transplant and HIV patients |
| Limitations: Limit of quantification for this DNA assay is 2.6 log copies/mL (390 copies/mL); if the assay DID NOT DETECT the virus, the test result will be reported as <2.6 log copies/mL (<390 copies/mL) If assay DETECTED presence of virus but was unable to accurately quantify number of copies, test result will be reported as not quantified |
| Test name: Cytomegalovirus Antibodies, IgG & IgM |
| ARUP #: 0050622 |
| Methodology: Refer to individual components. |
| Use: Diagnose pregnant women and infants possibly infected with CMV Discriminate between current (IgM) and prior infections (IgG) |
| Limitations: Not recommended for immunocompromised patients Rise in CMV antibody level may occur in patients with measles, VZV or HSV due to antigenic cross-reactivity within the herpesvirus family Infants may test positive during first 6 months due to maternal antibodies |
| Test name: Cytomegalovirus IgG Avidity (AviDx™), ELISA |
| ARUP #: 2003044 |
| Methodology: Enzyme-Linked Immunosorbent Assay |
| Use: Measure CMV IgG avidity to distinguish primary infection from non-primary infection during pregnancy |
| Test name: Cytomegalovirus Antibodies (Total) |
| ARUP #: 0050166 |
| Methodology: Solid Phase Agglutination |
| Use: Screen solid organ donors; not appropriate for tissues such as corneal |
| Limitations: Rise in CMV antibody levels may occur in patients with measles, VZV or HSV due to antigenic cross-reactivity within the herpesvirus family Test measures both IgG and IgM antibodies; test does not discriminate between passively acquired and actively produced antibody |
| Test name: Cytomegalovirus (CMV) by Immunohistochemistry |
| ARUP #: 2003833 |
| Methodology: Immunohistochemistry |
| Use: Aid in histologic diagnosis of CMV Stained and returned to client pathologist for interpretation; consultation available if needed |
| Test name: Cytomegalovirus Antibody, IgM |
| ARUP #: 0050553 |
| Methodology: Semi-Quantitative Enzyme-Linked Immunosorbent Assay |
| Comments: |
| Test name: Cytomegalovirus Antibody, IgG |
| ARUP #: 0050165 |
| Methodology: Chemiluminescent Immunoassay |
| Comments: |
| Test name: Cytomegalovirus Antiviral Drug Resistance by Sequencing |
| ARUP #: 2004760 |
| Methodology: Polymerase Chain Reaction/Sequencing |
| Comments: |
| Test name: TORCH Antibodies, IgG |
| ARUP #: 0050772 |
| Methodology: Chemiluminescent Immunoassay |
| Comments: |
| Test name: TORCH Antibodies, IgM |
| ARUP #: 0050665 |
| Methodology: Refer to individual components |
| Comments: |